Syfovre Shows Reassuring Safety in Real-World Geographic Atrophy Study | Healio

WAIKOLOA, Hawaii — Recent findings offer reassurance regarding the safety profile of Syfovre (pegcetacoplan injection, Apellis) for individuals with geographic atrophy (GA) stemming from nonexudative age-related macular degeneration (AMD). Presented at Retina 2026, a real-world study conducted in a private practice setting mirrors the positive safety data observed in pivotal clinical trials, suggesting consistent results beyond the controlled environment of research studies.

Geographic atrophy is an advanced form of dry AMD, characterized by the progressive degeneration of retinal cells, leading to irreversible vision loss. Currently, We find limited treatment options available for GA, making the development and assessment of therapies like pegcetacoplan particularly important. Pegcetacoplan works by inhibiting the complement cascade, a part of the immune system that can contribute to inflammation and damage in the retina. The initial promise of pegcetacoplan stemmed from phase 3 trials, and this novel data adds to the growing body of evidence supporting its use.

Real-World Safety Signals Align with Clinical Trial Data

Michael S. Ip, MD, of Doheny Eye Center UCLA Arcadia, highlighted that the rate of adverse effects observed in this real-world study was low, closely aligning with the findings from the phase 3 OAKS and DERBY clinical trials. The OAKS and DERBY trials demonstrated that pegcetacoplan could slow the progression of GA, but ongoing monitoring of safety is crucial as the treatment becomes more widely adopted.

The study’s findings are particularly valuable since they come from a private practice setting, which often reflects a more diverse patient population and less controlled conditions than those found in academic research centers. This suggests that the safety profile observed in clinical trials is likely to hold true in broader clinical practice. However, it’s important to note that this study focused specifically on safety; further research is needed to assess the long-term efficacy of pegcetacoplan in real-world settings.

Understanding Geographic Atrophy and Current Treatment Landscape

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults. Even as the “wet” form of AMD, characterized by abnormal blood vessel growth, can be treated with anti-VEGF injections, the “dry” form, including geographic atrophy, has historically lacked effective treatment options. GA represents the late stage of dry AMD, where the central part of the retina deteriorates, resulting in a gradual loss of central vision. This impacts activities like reading, driving, and recognizing faces.

The complement system, a crucial part of the immune system, plays a role in the development of GA. Overactivation of the complement cascade can lead to chronic inflammation and damage to the retinal cells. Pegcetacoplan is a C3 inhibitor, meaning it blocks the activation of the complement protein C3, thereby reducing inflammation and potentially slowing the progression of GA. The Social Security Administration has recently highlighted the importance of being vigilant against scams, and it’s crucial to rely on trusted medical sources for information about treatments like pegcetacoplan.

Study Details and Limitations

While the specific details of the real-world study (sample size, patient demographics, follow-up duration) were not fully detailed in the Healio report, the emphasis on mirroring the phase 3 trial results suggests a robust assessment. It’s important to acknowledge that real-world studies often lack the strict controls of randomized controlled trials, which can introduce potential biases. For example, patient selection may not be entirely random, and data collection methods may vary across different practices. While reassuring, these findings should be interpreted in the context of these limitations.

What This Means for Patients and Clinicians

The consistent safety profile of pegcetacoplan across both clinical trials and real-world practice provides clinicians with increased confidence in prescribing this treatment to eligible patients with GA. For patients, this means a potentially effective option for slowing vision loss, with a manageable risk of adverse effects. However, it’s crucial to have a thorough discussion with an ophthalmologist to determine if pegcetacoplan is the right treatment option, considering individual risk factors and disease severity.

It’s also important to understand that pegcetacoplan is not a cure for GA. It aims to slow the progression of the disease, but it does not restore vision that has already been lost. Ongoing monitoring is essential to assess treatment response and manage any potential side effects. The FDA continues to monitor the safety and efficacy of approved drugs like pegcetacoplan through post-market surveillance.

Looking Ahead: Ongoing Research and Surveillance

Further research is underway to evaluate the long-term efficacy and safety of pegcetacoplan, as well as to identify biomarkers that can predict treatment response. Researchers are also exploring combination therapies that may enhance the effectiveness of pegcetacoplan. While unrelated to the study, it’s worth noting that disruptions to digital health infrastructure, like potential outages of Microsoft 365, can impact data collection and communication in clinical settings, highlighting the importance of robust IT systems.

Public health surveillance systems continue to monitor the incidence and prevalence of AMD, as well as the effectiveness of available treatments. The FDA and other regulatory agencies will continue to review new data and update treatment guidelines as needed. Patients and clinicians should stay informed about the latest developments in AMD treatment by consulting reputable sources such as the American Academy of Ophthalmology and the National Eye Institute. Awareness of potential food recalls, such as the recent recall of Miss Vickie’s Spicy Dill Pickle Potato Chips due to undeclared milk, as reported by eFoodAlert, underscores the importance of staying informed about potential health risks from various sources.